<DOC>
	<DOCNO>NCT02975115</DOCNO>
	<brief_summary>This study design confirm efficacy dasatinib 100mg daily produce complete molecular response prove possibility `` Operational Cure '' CMR patient .</brief_summary>
	<brief_title>Evaluating True PCR-negative Rate Frontline Dasatinib Early Chronic Phase CML Therapeutic Harmonization</brief_title>
	<detailed_description>This study also examine kinetics complete molecular response use new highly sensitive PCR base technology , digital PCR , report sensitivity 6 log reduction .</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>Patients must Ph+ CML CP newly diagnose chronic phase CML , except hydroxyurea , anagrelide within 7 day imatinib treatment Subjects must enrol study within approximately 3 month ( 90 day ) date first diagnose CML . Subjects allow clonal chromosomal abnormality addition Philadelphia chromosome remain eligible 02 ECOG Performance Status ( PS ) Score Adequate hepatic function test Adequate renal function test Adequate organ function Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy WOCBP must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 72 hour prior start investigational product . Subjects agree sign inform consent WOCBP unwilling unable use acceptable method avoid pregnancy entire study period least one month ( 4 week ) least 1 month ( 4 week ) last dose study medication . WOCBP use prohibit contraceptive method ( Not applicable study ) . Women pregnant breastfeeding . Women positive pregnancy test enrollment prior administration study medication . Men whose sexual partner WOCBP , unwilling unable use acceptable method avoid pregnancy entire study period least one month ( 4 week ) completion study medication . A serious uncontrolled medical disorder active infection would impair ability subject receive protocol therapy . Known pleural effusion baseline . Uncontrolled significant cardiovascular disease History significant bleeding disorder unrelated CML Prior chemotherapy peripheral stem cell mobilization . ( Prior collection unmobilized peripheral blood stem cell permit ) . Prior concurrent malignancy Evidence digestive dysfunction would prevent administration study therapy mouth Uncontrolled diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>